Endoscopic ultrasound-guided stent-in-stent placement for management of migrated hepaticogastrostomy stent

Stent misdeployment or migration into the peritoneal cavity is a dreaded complication of endoscopic ultrasound (EUS)-guided hepaticogastrostomy. It occurs in around 2.5% procedures, is potentially fatal, and usually treated surgically [1]. A few cases have been reported in which this complication was managed by repositioning the stent using transluminal endoscopic surgery techniques [2, 3] or by EUS-guided stent-in-stent insertion [4, 5]. Here we present a case of EUS-guided puncture of the migrated stent through the wall of the gastroesophageal junction followed by stent-in-stent insertion.

A 58-year-old woman with a malignant hilar obstruction, a self-expandable metal stent (SEMS) in the right hepatic duct, and a failure to drain the left hepatic duct during endoscopic retrograde cholangiography underwent EUS-guided hepaticogastrostomy with a fully covered biliary SEMS (Hanarostent BCG-10-060; M.I. Tech, Gyeonggi-do, Republic of Korea). The next day the patient developed abdominal pain and vomiting. Computed tomography (CT) revealed stent migration into abdominal cavity and a fluid collection between the stomach and left liver lobe (Fig. 1).

The stent could not be identified in the hepaticogastrostomy site on endoscopy (Fig. 2), but it was well visible on EUS close to the gastroesophageal junction. Using fluoroscopy control of the echoendoscope tip position and EUS guidance, the proximal end of the stent was punctured with a 19G needle (Easy-Shot3 Plus; Olympus, Tokyo, Japan), followed by insertion of a 0.035-mm guidewire (Visiglide; Olympus), dilation of the track with a 6-mm balloon (Hurricane RX; Boston Scientific, Marlborough, Massachusetts, USA), and insertion of a partially covered SEMS, 10 cm in length, in a stent-in-stent fashion (Hanarostent, BPD-10-100; M.I. Tech) (Fig. 3–5, Video 1). The postprocedural course was uneventful, clinical symptoms sub-
sided, and bilirubin level dropped from 8.5 mg/dl to 3.1 mg/dl within 14 days allowing chemotherapy to resume. CT and endoscopy at 6 weeks confirmed the correct position of the salvage stent.

Competing interests

M. Polkowski has had consultancy and speaker agreements with Boston Scientific and Olympus. M. F. Kaminski has had speaker agreements with Olympus, Fujifilm, Medtronic, and Boston Scientific, consultancy agreements with Olympus and AlfaSigma, and received research support from Fujifilm.

Corresponding author

Marcin Polkowski, MD
Department of Gastroenterology
Hepatology and Clinical Oncology, Center of Postgraduate Medical Education,
Roentgena 5, 02-781 Warsaw, Poland
mp.polkowski@gmail.com

References


The authors

Marcin Polkowski1,2 Michal F. Kaminski1,2, Karolina Jasionek1,2, Jaroslaw Regula1,2
1 Department of Oncological Gastroenterology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2 Department of Gastroenterology, Hepatology and Clinical Oncology, Center of Postgraduate Medical Education, Warsaw, Poland